Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Aspirin  COVID-19 treatment studies for Aspirin  C19 studies: Aspirin  Aspirin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 11% Improvement Relative Risk ICU admission 22% Progression 9% c19early.org/e Lal et al. NCT04323787 Aspirin for COVID-19 Prophylaxis Is prophylaxis with aspirin beneficial for COVID-19? Retrospective 21,579 patients in the USA (February 2020 - September 2021) Lower mortality (p=0.01) and ICU admission (p<0.0001) Lal et al., Archivos de Bronconeumología, doi:10.1016/j.arbres.2022.07.017 Favors aspirin Favors control
Pre-hospital aspirin use and patient outcomes in COVID-19: Results from the International Viral Infection and Respiratory Illness Universal Study (VIRUS)
Lal et al., Archivos de Bronconeumología, doi:10.1016/j.arbres.2022.07.017 (date from earlier preprint), NCT04323787 (history)
Lal et al., Pre-hospital aspirin use and patient outcomes in COVID-19: Results from the International Viral Infection and.., Archivos de Bronconeumología, doi:10.1016/j.arbres.2022.07.017 (date from earlier preprint), NCT04323787
May 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 21,579 hospitalized COVID-19 patients mostly in the USA, showing lower risk of mortality and severity with existing aspirin use.
risk of death, 11.0% lower, HR 0.89, p = 0.01, treatment 4,691, control 16,888, adjusted per study, multivariable.
risk of ICU admission, 22.0% lower, HR 0.78, p < 0.001, treatment 4,691, control 16,888, adjusted per study, multivariable.
risk of progression, 9.0% lower, HR 0.91, p = 0.02, treatment 4,691, control 16,888, adjusted per study, multivariable.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Lal et al., 5 May 2022, retrospective, USA, peer-reviewed, 20 authors, study period 15 February, 2020 - 30 September, 2021, trial NCT04323787 (history).
Contact: lal.amos@mayo.edu.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperAspirinAll
Pre-hospital Aspirin Use and Patient Outcomes in COVID-19: Results from the International Viral Infection and Respiratory Illness Universal Study (VIRUS)
Amos Lal, Juan Pablo Domecq Garces, Vikas Bansal, Aysun Tekin, Simon Zec, Ashish K Khanna, Matthew A Warner, Amy B Christie, Rodrigo Cartin-Ceba, Valerie M Banner-Goodspeed, Donna Lee Armaignac, Sreekanth R Cheruku, Umamaheswara Raju, Yasir Tarabichi, Joshua L Denson, Vishakha Kumar, Allan Walkey, Karen Boman, Neha Deo, Rahul Kashyap, Ognjen Gajic
Archivos de Bronconeumología, doi:10.1016/j.arbres.2022.07.017
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Conflict of Interest
References
Ackermann, Verleden, Kuehnel, Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19, New England Journal of Medicine
Beigel, Tomashek, Dodd, Remdesivir for the treatment of Covid-19, New England Journal of Medicine
Beltramo, Cottenet, Mariet, Chronic respiratory diseases are predictors of severe outcome in COVID-19 hospitalised patients: a nationwide study, European Respiratory Journal
Carestia, Davis, Grosjean, Acetylsalicylic acid inhibits intravascular coagulation during Staphylococcus aureus-induced sepsis in mice, Blood
Chelucci, Boncinelli, Marsili, Aspirin effect on early and late changes in acute lung injury in sheep, Intensive care medicine
Chow, Khanna, Kethireddy, Aspirin Use Is Associated With Decreased Mechanical Ventilation, Intensive Care Unit Admission, and In-Hospital Mortality in Hospitalized Patients With Coronavirus Disease, Anesthesia & Analgesia
Chow, Rahnavard, Gomberg-Maitland, Association of Early Aspirin Use With In-Hospital Mortality in Patients With Moderate COVID-19, JAMA Netw Open
Chow, Yin, Yamane, Association of prehospital antiplatelet therapy with survival in patients hospitalized with COVID-19: A propensity score-matched analysis, Journal of Thrombosis and Haemostasis
Christie, Ashley, Mayo, Arizona, Cartin-Ceba et al., The study was performed in collaboration with or on behalf of The Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS): COVID-19 Registry Investigator Group Atrium Health Navicent
De Almeida-Pititto, Dualib, Zajdenverg, Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis, Diabetology & Metabolic Syndrome
Domecq, Lal, Sheldrick, Outcomes of Patients With Coronavirus Disease 2019 Receiving Organ Support Therapies: The International Viral Infection and Respiratory Illness Universal Study Registry, Critical care medicine
Gansevoort, Hilbrands, CKD is a key risk factor for COVID-19 mortality, Nature Reviews Nephrology
Garcia, Johnson, Bosch, From The Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study: Coronavirus Disease 2019 Registry Investigator Group, Critical Care Explorations
Gold, Rossen, Ahmad, Race, ethnicity, and age trends in persons who died from COVID-19-United States, May, Morbidity and Mortality Weekly Report
Harris, Taylor, Thielke, Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support, Journal of biomedical informatics
Jiménez, García-Sanchez, Rali, Incidence of VTE and bleeding among hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis, Chest
Klok, Kruip, Van Der Meer, Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis, Thrombosis research
Kompaniyets, Goodman, Belay, Body mass index and risk for COVID-19-related hospitalization, intensive care unit admission, invasive mechanical ventilation, and death-united states, march-december 2020, Morbidity and Mortality Weekly Report
Kor, Carter, Park, Effect of Aspirin on Development of ARDS in At-Risk Patients Presenting to the Emergency Department: The LIPS-A Randomized Clinical Trial, Jama
Kor, Erlich, Gong, Association of pre-hospitalization aspirin therapy and acute lung injury: results of a multicenter international observational study of at-risk patients, Critical care medicine
Kor, Talmor, Banner-Goodspeed, Lung Injury Prevention with Aspirin (LIPS-A): a protocol for a multicentre randomised clinical trial in medical patients at high risk of acute lung injury, BMJ Open
Kunutsor, Laukkanen, Incidence of venous and arterial thromboembolic complications in COVID-19: a systematic review and meta-analysis, Thrombosis research
Lal, Mishra, Akhtar, Pneumothorax and pneumomediastinum in COVID-19 acute respiratory distress syndrome, Monaldi Arch Chest Dis
Liang, Zhang, Li, Coronary heart disease and COVID-19: A meta-analysis
Looney, Nguyen, Hu, Platelet depletion and aspirin treatment protect mice in a two-event model of transfusion-related acute lung injury, The Journal of clinical investigation
Lopez-Leon, Wegman-Ostrosky, Perelman, More than 50 Long-term effects of COVID-19: a systematic review and meta-analysis
Lu, Pan, Zhang, A meta-analysis of the incidence of venous thromboembolic events and impact of anticoagulation on mortality in patients with COVID-19
Malas, Naazie, Elsayed, Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis, EClinicalMedicine
Osborne, Veigulis, Arreola, Association of mortality and aspirin prescription for COVID-19 patients at the Veterans Health Administration, PLoS ONE
Salah, Mehta, Meta-Analysis of the Effect of Aspirin on Mortality in COVID-19, Am J Cardiol
Ssentongo, Ssentongo, Heilbrunn, Association of cardiovascular disease and 10 other pre-existing comorbidities with COVID-19 mortality: A systematic review and metaanalysis, PLoS ONE
Vincent, Taccone, Understanding pathways to death in patients with COVID-19
Walkey, Kumar, Harhay, The Viral Infection and Respiratory Illness Universal Study (VIRUS): An International Registry of Coronavirus 2019-Related Critical Illness, Crit Care Explor
Who, Global COVID-19 clinical platform: case report form for suspected cases of multisystem inflammatory syndrome (MIS) in children and adolescents temporally related to COVID-19
Wijaya, Andhika, Huang, The effects of aspirin on the outcome of COVID-19: A systematic review and meta-analysis, Clin Epidemiol Glob Health
Zarbock, Ley, The role of platelets in acute lung injury (ALI). Frontiers in bioscience: a journal and virtual library
Zarbock, Polanowska-Grabowska, Ley, Platelet-neutrophil-interactions: linking hemostasis and inflammation, Blood reviews
Zhao, Bai, Su, Long-term effects on survivors with COVID-19, The Lancet
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit